Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $18.02M
• Dividend Yield: N/A
• Average Volume (3M): 25.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: -22.38%
• EPS Growth: 56.66%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 72,657
• 30 Day Avg. Volume: 25,639
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.01
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 60.15
• Enterprise Value/Revenue: 2.96
• Enterprise Value/Gross Profit: -25.90
• Enterprise Value/Ebitda: -3.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $4.00 ▲(3.09% Upside)

Concord Medical Services is facing significant financial challenges, with negative earnings and cash flows, and a heavily leveraged balance sheet. Technical indicators also suggest a bearish outlook, and valuation metrics are poor, reflecting the company's ongoing struggles.

Positive Factors

Proton Therapy Expansion

The commencement of proton therapy operations at Guangzhou Concord Cancer Hospital has improved financials and is expected to enhance patient outcomes, indicating a strategic focus on advanced treatment technologies.

Strategic Market Presence

The listing of Concord Healthcare’s H shares on the Hong Kong Stock Exchange enhances market presence and financial transparency, supporting long-term growth and investor confidence.

Innovative Treatment Milestone

Achieving the first proton therapy for eye cancer in China positions Concord Medical as a leader in innovative oncology treatments, potentially expanding its market share in specialized care.

Negative Factors

Revenue Decline

A sharp revenue drop from $537M in 2023 to $384M in 2024 highlights ongoing operational challenges, potentially affecting long-term financial stability and growth prospects.

High Leverage

The heavily leveraged balance sheet with negative equity indicates high financial risk, limiting the company's ability to invest in growth opportunities and manage economic downturns.

Negative Cash Flows

Persistent negative cash flows suggest unsustainable reliance on external financing, which could hinder long-term operational viability and strategic investments.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services (CCM) is a leading provider of comprehensive cancer treatment and diagnostic services in China. The company operates a network of radiotherapy and diagnostic centers, focusing on advanced treatment technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS). With a strong emphasis on patient care and innovative medical practices, CCM aims to enhance cancer treatment outcomes through a combination of state-of-the-art facilities and skilled healthcare professionals.

How the Company Makes Money

Concord Medical Services generates revenue primarily through its cancer treatment services, including radiation therapy, diagnostic imaging, and related healthcare services. The company charges patients and insurance providers for these services, which often involve complex procedures and advanced technology. Key revenue streams include direct payments from patients, reimbursements from government health insurance programs, and private health insurance plans. Additionally, CCM may benefit from partnerships with hospitals and medical institutions, allowing for referrals and collaborative treatment plans, which can further enhance its revenue generation. The company's focus on expanding its network of treatment centers and leveraging technological advancements in cancer care also plays a crucial role in driving its profitability.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is experiencing severe financial distress, with declining revenues, negative profit margins, and a heavily leveraged balance sheet. Persistent negative cash flows further emphasize the need for strategic restructuring.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	365.76M	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-41.85M	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-358.51M	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-163.12M	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.73B	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	177.39M	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.82B	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	5.01B	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.24B	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	0.00	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	0.00	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	0.00	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	0.00	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 3.88 is below the 20-day moving average (MA) of 4.10, below the 50-day MA of 4.73, and below the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 40.78 is Neutral, neither overbought nor oversold. The STOCH value of 6.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JYNT	54 Neutral	$133.80M	71.15	-1.37%	―	-54.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.61M	-6.23	-8.75%	―	17.84%	-156.13%
DCGO	49 Neutral	$87.05M	-1.68	-17.32%	―	-47.03%	-274.41%
CCEL	44 Neutral	$29.80M	-62.18	―	10.87%	-0.29%	94.56%
PIII	39 Underperform	$29.69M	-0.08	-257.39%	―	-2.15%	-6.72%
CCM	38 Underperform	$18.02M	-0.74	―	―	-22.38%	56.66%

Concord Medical Services Corporate Events

Concord Medical Announces 2025 Shareholder Meeting

On December 2, 2025, Concord Medical Services announced its 2025 annual general meeting of shareholders scheduled for December 29, 2025, in Beijing. The meeting will not involve any proposals for shareholder approval but will serve as a platform for shareholders to discuss company affairs with management. This event underscores Concord Medical’s commitment to transparency and stakeholder engagement, potentially impacting its operational strategies and market perception.

Concord Medical Services Announces Director Resignation

On September 28, 2025, Mr. Yue Yu resigned as a Director of Concord Medical Services Holdings Limited, effective September 29, 2025, citing personal reasons. His resignation was not due to any disagreements with the company’s operations or policies, ensuring a smooth transition without impacting the company’s strategic direction.

Concord Medical Reports Improved Financials Amid Proton Therapy Expansion

Concord Medical Services announced its unaudited financial results for the first half of 2025, revealing a total net revenue of RMB200.6 million, an 8.3% decrease from the previous year. Despite a net loss of RMB27.1 million, the company showed significant improvement in its gross loss margin, which decreased from 19.0% to 2.1%, largely due to the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital. This advancement has contributed to increased revenues in the hospital business, while the network business faced challenges due to decreased demand for medical equipment and software. The company remains committed to advancing proton therapy and enhancing operational efficiency, which is expected to improve patient outcomes and expand access to advanced diagnostic and therapeutic technologies.